Taken together, these data add extra experimental support to the notion that this enzymatic pathway and its metabolic products play a direct role in the development of the entire tau pathological phenotype, and for this reason, it is a viable therapeutic target with true modifying‐disease potential for the treatment human tauopathies. This evidence concerns the gene MAPT and tauopathy.